Analysis of commercial insurance claims reveals which factors predict semaglutide initiation among adults with obesity but no diabetes.
JAMA Network OpenLarge claims database study identifying predictors of semaglutide initiation for obesity
What the researchers found
Identified demographic and clinical factors associated with semaglutide initiation for obesity in commercially insured adults without diabetes.
Why it matters
Understanding who accesses new obesity medications reveals potential disparities and informs efforts to ensure equitable treatment access.
The numbers in context
US adults aged 18+ with first obesity diagnosis June 2021-July 2022. Excluded prior AOM, GLP-1, bariatric surgery, or diabetes claims. Continuous enrollment required.
How the study worked
Retrospective observational cohort study using MarketScan Commercial Claims and Encounters Database.
Who was studied
Commercially insured US adults with newly diagnosed obesity without diabetes
What this study cannot tell us
Only commercially insured patients — excludes Medicare, Medicaid, and uninsured. Observational design cannot establish causation.
How to read the evidence
Large retrospective cohort from a national claims database — strong for identifying associations but limited by claims data completeness.
When this study was published
Published in 2025, covering the first year after semaglutide's obesity approval.
The bigger picture
As anti-obesity medications become more mainstream, identifying access patterns helps address healthcare equity and coverage policy.
Questions still open
- Do access disparities differ across insurance types?
- How have initiation patterns changed since 2022 as awareness and supply have evolved?
Common questions
Who is most likely to start semaglutide for weight loss?
Is semaglutide access equitable?
Read the original research
Factors Associated With Semaglutide Initiation Among Adults With Obesity.
JAMA network open, 8(1), e2455222
Citation
Podolsky, Meghan I; Raquib, Rafeya; Shafer, Paul R; Hempstead, Katherine; Ellis, Randall P; Stokes, Andrew C. (2025). Factors Associated With Semaglutide Initiation Among Adults With Obesity.. JAMA network open, 8(1), e2455222. https://doi.org/10.1001/jamanetworkopen.2024.55222